We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

148 hedge funds and large institutions have $2.77B invested in Loxo Oncology, Inc in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 56 increasing their positions, 44 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 14

27% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 44

16% more capital invested

Capital invested by funds: $2.4B → $2.77B (+$377M)

15% more funds holding

Funds holding: 129148 (+19)

27% less funds holding in top 10

Funds holding in top 10: 118 (-3)

29% less call options, than puts

Call options by funds: $8.15M | Put options by funds: $11.5M

Holders
148
Holders Change
+19
Holders Change %
+14.73%
% of All Funds
3.69%
Holding in Top 10
8
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-27.27%
% of All Funds
0.2%
New
34
Increased
56
Reduced
44
Closed
14
Calls
$8.15M
Puts
$11.5M
Net Calls
-$3.38M
Net Calls Change
+$240K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
26
BVF Inc
California
$22M -$17.5M -225,000 -49%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$20M +$2.9M +37,372 +21%
Renaissance Technologies
28
Renaissance Technologies
New York
$19.1M +$16.1M +207,100 New
UBS AM
29
UBS AM
Illinois
$19.1M -$2.59M -33,297 -14%
Norges Bank
30
Norges Bank
Norway
$17.1M +$14.5M +186,162 New
Deutsche Bank
31
Deutsche Bank
Germany
$16.4M +$9.66M +124,383 +233%
DM
32
Deerfield Management
New York
$15.6M -$6.38M -82,167 -33%
MWNA
33
Marshall Wace North America
New York
$12.7M -$21.6M -278,569 -67%
OM
34
Opaleye Management
Massachusetts
$12M
Ameriprise
35
Ameriprise
Minnesota
$11.7M -$661K -8,510 -6%
AIC
36
AWM Investment Company
New York
$11.5M -$2.72M -35,000 -22%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$11.2M +$312K +4,018 +3%
Goldman Sachs
38
Goldman Sachs
New York
$10.9M +$2.25M +28,983 +32%
Charles Schwab
39
Charles Schwab
California
$9.74M +$1.87M +24,025 +29%
CS
40
Candriam SCA
Luxembourg
$9.43M +$2.21M +28,400 +38%
AAMU
41
Amundi Asset Management US
Massachusetts
$9.35M -$11.2K -144 -0.1%
Axa
42
Axa
France
$8.99M -$1.23M -15,821 -14%
BBA
43
Baker Bros. Advisors
New York
$8.85M -$3.28M -42,250 -31%
CLCM
44
Crawford Lake Capital Management
New Jersey
$7.53M -$3.76M -48,426 -37%
USAA
45
United Services Automobile Association
Texas
$6.99M +$145K +1,870 +3%
SSA
46
Schonfeld Strategic Advisors
New York
$6.91M -$1.94M -25,000 -25%
RPAM
47
Rhenman & Partners Asset Management
Sweden
$6.91M +$5.83M +75,000 New
TCIM
48
TIAA CREF Investment Management
New York
$6.6M +$1.3M +16,695 +30%
CS
49
Credit Suisse
Switzerland
$6.53M +$1.06M +13,613 +24%
NIP
50
Nicholas Investment Partners
California
$5.43M -$302K -3,889 -6%

LOXO Hedge Fund Activity: Q3 2017 in Review

148 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q3 2017, worth a combined $2.77B — up 16% from $2.4B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new LOXO positions and 14 closed out — a net gain of 20 holders — while 56 added to existing stakes and 44 trimmed.

The largest buyer was Columbia Wanger Asset Management, opening a new position worth an estimated $41.5M. The largest seller was Paulson & Co, cutting an estimated $51.6M.

  • 148 institutional investors held Loxo Oncology, Inc (LOXO) as of Q3 2017, up from 129 in Q2 2017.
  • Funds reported $2.77B of Loxo Oncology, Inc stock for Q3 2017, up 16% quarter-over-quarter.
  • 34 funds opened new Loxo Oncology, Inc positions in Q3 2017 and 14 closed out, a net change of +20 holders.
  • The largest Loxo Oncology, Inc buyer in Q3 2017 was Columbia Wanger Asset Management, an estimated $41.5M added.
  • The largest Loxo Oncology, Inc seller in Q3 2017 was Paulson & Co, an estimated $51.6M sold.

Based on aggregated 13F filings for Q3 2017.